Abstract
Purpose. The objective was to compare the salivary protein profiles of saliva specimens from individuals diagnosed with invasive ductal carcinoma of the breast (IDC) with and without lymph node involvement. Methods. Three pooled saliva specimens from women were analyzed. One pooled specimen was from healthy women; another was from women diagnosed with Stage IIa IDC and a specimen from women diagnosed with Stage IIb. The pooled samples were trypsinized and the peptide digests labeled with the appropriate iTRAQ reagent. Labeled peptides from each of the digests were combined and analyzed by reverse phase capillary chromatography on an LC-MS/MS mass spectrometer. Results. The results yielded approximately 174 differentially expressed proteins in the saliva specimens. There were 55 proteins that were common to both cancer stages in comparison to each other and healthy controls while there were 20 proteins unique to Stage IIa and 28 proteins that were unique to Stage IIb.
Highlights
Clinicopathologic factors such as histologic type, tumor size, tumor grade, HER-2/neu over-expression, hormone receptor status, and lymph node involvement are recognized as having prognostic use in breast cancer management [1,2,3,4]
The authors have examined the salivary proteome that is altered in the presence of carcinoma of the breast with and without lymph node metastasis
P value .0127 .0324 .0254 .0000 .0000 .0465 .0183 .0194 .0005 .0108 .0000 .0022 .0165 .0129 .0000 .0336 .0000 .0002 .0279 .0016 .0000 .0131 .0077 .0004 .0000 .0000 .0000 .0027 .0000 .0093 .0000 .0383 .0007 .0424 emphasize the findings at this point, but we are encouraged to find that these protein profiles are found to be altered in the supernants from cancer tissues which provide additional support to our findings
Summary
Clinicopathologic factors such as histologic type, tumor size, tumor grade, HER-2/neu over-expression, hormone receptor status, and lymph node involvement are recognized as having prognostic use in breast cancer management [1,2,3,4]. Assessed, axillary lymph node metastasis is the most important prognostic factor predicting breast cancer patient survival [5,6,7]. The best predictor of axillary lymph node metastasis is the presence or absence of metastasis in the sentinel lymph node. Current methodologies for this assessment are limited to axillary lymph node dissection and sentinel lymph node biopsy; these procedures are not without risks. Newer, more accurate, and less invasive means of predicting axillary lymph node metastasis would greatly improve breast cancer patient management and quality of life
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
